- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 90,770 | 04.07.24 16:41:49 | -0,210 | -0,23% | 90,960 | 90,970 | 90,680 | 90,980 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 944,800 | 04.07.24 08:04:14 | +8,200 | +0,88% | 943,800 | 949,800 | 944,800 | 936,600 |
